{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:09:26Z","timestamp":1785251366093,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"DOI":"10.1007\/s10143-025-03909-z","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:20:20Z","timestamp":1762147220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The clinical outcomes of combined stereotactic radiosurgery with PD-1\/PD-L1 inhibitors in patients with metastatic brain tumors: a systematic review and meta-analysis on the safety and efficacy"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8485-8721","authenticated-orcid":false,"given":"Muhammad Hussain","family":"Ahmadvand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-6925","authenticated-orcid":false,"given":"Mohammad Amin","family":"Habibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7553-1016","authenticated-orcid":false,"given":"Mohammad Sina","family":"Mirjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0521-8420","authenticated-orcid":false,"given":"Amirmohammad","family":"Bahri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fateme","family":"Aghaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirmahdi","family":"Foroughi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5419-4152","authenticated-orcid":false,"given":"Yalda","family":"Ghazizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Shahir Eftekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Gandomkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouria","family":"Delbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8862-0778","authenticated-orcid":false,"given":"Ibrahim","family":"Mohammadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8801-1158","authenticated-orcid":false,"given":"Bardia","family":"Hajikarimloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salem M.","family":"Tos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6605-822X","authenticated-orcid":false,"given":"Milad","family":"Shafizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason P.","family":"Sheehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"2","key":"3909_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-019-0548-3","volume":"21","author":"J Kraft","year":"2019","unstructured":"Kraft J et al (2019) Stereotactic radiosurgery for multiple brain metastases. Curr Treat Options Neurol 21(2):6","journal-title":"Curr Treat Options Neurol"},{"key":"3909_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00959","volume":"9","author":"DM Routman","year":"2018","unstructured":"Routman DM et al (2018) Preoperative stereotactic radiosurgery for brain metastases. Front Neurol 9:959","journal-title":"Front Neurol"},{"issue":"3","key":"3909_CR3","first-page":"357","volume":"60","author":"HM Specht","year":"2016","unstructured":"Specht HM, Combs SE (2016) Stereotactic radiosurgery of brain metastases. J Neurosurg Sci 60(3):357\u2013366","journal-title":"J Neurosurg Sci"},{"issue":"3","key":"3909_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2217\/cns-2016-0025","volume":"5","author":"S Myrehaug","year":"2016","unstructured":"Myrehaug S et al (2016) Why hypofractionate stereotactic radiosurgery for brain metastases? CNS Oncol 5(3):111\u2013113","journal-title":"CNS Oncol"},{"key":"3909_CR5","doi-asserted-by":"crossref","unstructured":"Bodensohn R et al (2023) Stereotactic radiosurgery of multiple brain metastases: A review of treatment techniques, vol 15. Cancers (Basel), 22","DOI":"10.3390\/cancers15225404"},{"issue":"1","key":"3909_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-023-02389-z","volume":"18","author":"I Gruber","year":"2023","unstructured":"Gruber I et al (2023) Stereotactic radiosurgery of brain metastases: a retrospective study. Radiat Oncol 18(1):202","journal-title":"Radiat Oncol"},{"issue":"3","key":"3909_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2217\/fon-2021-0795","volume":"18","author":"W Li","year":"2022","unstructured":"Li W et al (2022) Efficacy of PD-1\/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials. Future Oncol 18(3):403\u2013412","journal-title":"Future Oncol"},{"issue":"6","key":"3909_CR8","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/CMR.0000000000000700","volume":"30","author":"M Marcaillou","year":"2020","unstructured":"Marcaillou M et al (2020) PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma. Melanoma Res 30(6):580\u2013589","journal-title":"Melanoma Res"},{"issue":"16","key":"3909_CR9","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1158\/1078-0432.CCR-20-0798","volume":"26","author":"I Eguren-Santamaria","year":"2020","unstructured":"Eguren-Santamaria I et al (2020) PD-1\/PD-L1 blockers in NSCLC brain metastases: challenging paradigms and clinical practice. Clin Cancer Res 26(16):4186\u20134197","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3909_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00412-3","volume":"12","author":"H Wang","year":"2023","unstructured":"Wang H et al (2023) Outcome differences between PD-1\/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases. Exp Hematol Oncol 12(1):56","journal-title":"Exp Hematol Oncol"},{"key":"3909_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007239","author":"MS Phadke","year":"2023","unstructured":"Phadke MS et al (2023) Differential requirements for CD4\u2009+\u2009T cells in the efficacy of the anti-PD-1\u2009+\u2009LAG-3 and anti-PD-1\u2009+\u2009CTLA-4 combinations in melanoma flank and brain metastasis models. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2023-007239","journal-title":"J Immunother Cancer"},{"key":"3909_CR12","first-page":"n71","volume":"372","author":"JP Matthew","year":"2021","unstructured":"Matthew JP et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"6","key":"3909_CR13","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","volume":"16","author":"NU Lin","year":"2015","unstructured":"Lin NU et al (2015) Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 16(6):e270\u2013e278","journal-title":"Lancet Oncol"},{"issue":"12","key":"3909_CR14","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1093\/annonc\/mdw417","volume":"27","author":"KA Ahmed","year":"2016","unstructured":"Ahmed KA et al (2016) Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF\/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. Ann Oncol 27(12):2288\u20132294","journal-title":"Ann Oncol"},{"issue":"2","key":"3909_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s11060-017-2437-5","volume":"133","author":"KA Ahmed","year":"2017","unstructured":"Ahmed KA et al (2017) Outcomes targeting the PD-1\/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. J Neurooncol 133(2):331\u2013338","journal-title":"J Neurooncol"},{"issue":"15suppl","key":"3909_CR16","volume":"39","author":"KA Ahmed","year":"2021","unstructured":"Ahmed KA et al (2021) Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: a non-randomized, open-label phase Ib study. J Clin Oncol 39(15suppl):e14010\u2013e14010","journal-title":"J Clin Oncol"},{"key":"3909_CR17","doi-asserted-by":"crossref","unstructured":"Altan M et al (2023) Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I\/II trial. J Immunother Cancer, 11(7)","DOI":"10.1136\/jitc-2023-006871corr1"},{"issue":"1","key":"3909_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0282-x","volume":"5","author":"ES Anderson","year":"2017","unstructured":"Anderson ES et al (2017) Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment. J Immunother Cancer 5(1):76","journal-title":"J Immunother Cancer"},{"key":"3909_CR19","volume":"39","author":"R Bodensohn","year":"2023","unstructured":"Bodensohn R et al (2023) Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: a retrospective monocentric toxicity analysis. Clin Transl Radiat Oncol 39:100573","journal-title":"Clin Transl Radiat Oncol"},{"key":"3909_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejca.2020.04.028","volume":"135","author":"R Carron","year":"2020","unstructured":"Carron R et al (2020) Stereotactic radiosurgery combined with anti-PD1 for the management of melanoma brain metastases: a retrospective study of safety and efficacy. Eur J Cancer 135:52\u201361","journal-title":"Eur J Cancer"},{"key":"3909_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ejca.2017.01.007","volume":"75","author":"ES Choong","year":"2017","unstructured":"Choong ES et al (2017) Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. Eur J Cancer 75:169\u2013178","journal-title":"Eur J Cancer"},{"issue":"9","key":"3909_CR22","doi-asserted-by":"publisher","first-page":"9974","DOI":"10.21037\/apm-21-2334","volume":"10","author":"Y Huang","year":"2021","unstructured":"Huang Y et al (2021) Programmed cell death 1 inhibitors with or without concurrent brain radiotherapy for lung cancer patients with brain metastases. Ann Palliat Med 10(9):9974\u20139983","journal-title":"Ann Palliat Med"},{"issue":"4","key":"3909_CR23","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jtho.2018.01.012","volume":"13","author":"HG Hubbeling","year":"2018","unstructured":"Hubbeling HG et al (2018) Safety of combined PD-1 pathway inhibition and intracranial radiation therapy in non-small cell lung cancer. J Thorac Oncol 13(4):550\u2013558","journal-title":"J Thorac Oncol"},{"issue":"8","key":"3909_CR24","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1093\/neuonc\/noz046","volume":"21","author":"R Kotecha","year":"2019","unstructured":"Kotecha R et al (2019) The impact of sequencing PD-1\/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis. Neuro Oncol 21(8):1060\u20131068","journal-title":"Neuro Oncol"},{"issue":"2","key":"3909_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/CMR.0000000000000413","volume":"28","author":"C Nardin","year":"2018","unstructured":"Nardin C et al (2018) Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases. Melanoma Res 28(2):111\u2013119","journal-title":"Melanoma Res"},{"issue":"19","key":"3909_CR26","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1002\/cncr.30138","volume":"122","author":"JM Qian","year":"2016","unstructured":"Qian JM et al (2016) Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer 122(19):3051\u20133058","journal-title":"Cancer"},{"issue":"3","key":"3909_CR27","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ijrobp.2018.02.175","volume":"101","author":"E Schapira","year":"2018","unstructured":"Schapira E et al (2018) Improved overall survival and locoregional disease control with concurrent PD-1 pathway inhibitors and stereotactic radiosurgery for lung cancer patients with brain metastases. Int J Radiat Oncol Biol Phys 101(3):624\u2013629","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"3909_CR28","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3171\/2018.10.JNS181371","volume":"132","author":"C Singh","year":"2020","unstructured":"Singh C et al (2020) Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases. J Neurosurg 132(2):512\u2013517","journal-title":"J Neurosurg"},{"issue":"1","key":"3909_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2020.08.017","volume":"6","author":"RL Travis","year":"2021","unstructured":"Travis RL et al (2021) Control and toxicity in melanoma versus other brain metastases in response to combined radiosurgery and PD-(L)1 immune checkpoint inhibition. Adv Radiat Oncol 6(1):100561","journal-title":"Adv Radiat Oncol"},{"key":"3909_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19092653","author":"M Trommer-Nestler","year":"2018","unstructured":"Trommer-Nestler M et al (2018) Robotic stereotactic radiosurgery in melanoma patients with brain metastases under simultaneous anti-PD-1 treatment. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms19092653","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3909_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdad018","volume":"5","author":"P Wong","year":"2023","unstructured":"Wong P et al (2023) Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases. Neuro-Oncol Adv 5(1):vdad018","journal-title":"Neuro-Oncol Adv"},{"issue":"3","key":"3909_CR32","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ijrobp.2018.02.175","volume":"101","author":"E Schapira","year":"2018","unstructured":"Schapira E et al (2018) Improved overall survival and locoregional disease control with concurrent PD-1 pathway inhibitors and stereotactic radiosurgery for lung cancer patients with brain metastases. Int J Radiat Oncol Biol Phys 101(3):624\u2013629","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"3909_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2021.100798","volume":"6","author":"KA Ahmed","year":"2021","unstructured":"Ahmed KA et al (2021) Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: a nonrandomized, open-label phase 1b study. Adv Radiat Oncol 6(6):100798","journal-title":"Adv Radiat Oncol"},{"issue":"6","key":"3909_CR34","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.3171\/jns.2002.97.6.1276","volume":"97","author":"JP Sheehan","year":"2002","unstructured":"Sheehan JP et al (2002) Radiosurgery for non-small cell lung carcinoma metastatic to the brain: long-term outcomes and prognostic factors influencing patient survival time and local tumor control. J Neurosurg 97(6):1276\u20131281","journal-title":"J Neurosurg"},{"issue":"3","key":"3909_CR35","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1269\/jrr.90130","volume":"51","author":"Y Mariya","year":"2010","unstructured":"Mariya Y et al (2010) Outcome of stereotactic radiosurgery for patients with non-small cell lung cancer metastatic to the brain. J Radiat Res 51(3):333\u2013342","journal-title":"J Radiat Res"},{"issue":"Suppl","key":"3909_CR36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3171\/sup.2005.102.s_supplement.0075","volume":"102","author":"M Gerosa","year":"2005","unstructured":"Gerosa M et al (2005) Analysis of long-term outcomes and prognostic factors in patients with non-small cell lung cancer brain metastases treated by gamma knife radiosurgery. J Neurosurg 102(Suppl):75\u201380","journal-title":"J Neurosurg"},{"key":"3909_CR37","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.radonc.2018.08.025","volume":"130","author":"EJ Lehrer","year":"2019","unstructured":"Lehrer EJ et al (2019) Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data. Radiother Oncol 130:104\u2013112","journal-title":"Radiother Oncol"},{"issue":"1","key":"3909_CR38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/jrr\/rru092","volume":"56","author":"K Tamari","year":"2015","unstructured":"Tamari K et al (2015) Treatment outcomes using cyberknife for brain metastases from lung cancer. J Radiat Res 56(1):151\u2013158","journal-title":"J Radiat Res"},{"issue":"8","key":"3909_CR39","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi HA et al (2018) Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med 379(8):722\u2013730","journal-title":"N Engl J Med"},{"issue":"25","key":"3909_CR40","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1200\/JCO.2018.78.7622","volume":"36","author":"SC Formenti","year":"2018","unstructured":"Formenti SC, Demaria S (2018) Understanding responses to stereotactic body radiotherapy and pembrolizumab. J Clin Oncol 36(25):2661\u20132662","journal-title":"J Clin Oncol"},{"key":"3909_CR41","doi-asserted-by":"crossref","unstructured":"Sun L et al (2020) Clinical efficacy and safety of anti-PD-1\/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. Sci Rep, 10(1): p. 2083","DOI":"10.1038\/s41598-020-58674-4"},{"key":"3909_CR42","doi-asserted-by":"publisher","first-page":"8903","DOI":"10.2147\/IJGM.S333890","volume":"14","author":"M Khan","year":"2021","unstructured":"Khan M et al (2021) Anti-PD1 therapy plus Whole-Brain radiation therapy May prolong PFS in selected Non-Small cell lung cancer patients with brain metastases: A retrospective study. Int J Gen Med 14:8903\u20138918","journal-title":"Int J Gen Med"},{"issue":"4","key":"3909_CR43","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.ijrobp.2017.11.041","volume":"100","author":"L Chen","year":"2018","unstructured":"Chen L et al (2018) Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma. Int J Radiat Oncol Biol Phys 100(4):916\u2013925","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"3909_CR44","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long GV et al (2018) Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 19(5):672\u2013681","journal-title":"Lancet Oncol"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-025-03909-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-025-03909-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-025-03909-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T04:17:29Z","timestamp":1772079449000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-025-03909-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3909"],"URL":"https:\/\/doi.org\/10.1007\/s10143-025-03909-z","relation":{},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"11 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is deemed to exempt to received ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"756"}}